Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2023-06-30 Regulatory Filings
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen et GENFIT annoncent les résultats positifs de l'essai de Phase III ELATIVE évaluant elafibranor chez des patients atteints de cholangite biliaire primitive, une maladie cholestatique rare du foi
Regulatory Filings Classification · 1% confidence The document is a press release jointly issued by Ipsen and GENFIT on June 30, 2023, announcing positive Phase III trial results (ELATIVE®) for the drug elafibranor in treating Primary Biliary Cholangitis (PBC). It details efficacy endpoints, safety profiles, and future regulatory submission intentions (FDA and EMA). This content structure—announcing clinical trial results, providing key data points, and discussing future regulatory steps—is characteristic of an Earnings Release (ER) or a specific type of corporate announcement related to clinical progress. Since it is a detailed announcement of clinical trial results rather than a full financial report (10-K) or a brief earnings highlight (ER), and it is not a transcript (CT) or a formal presentation (IP), the most fitting category for a major clinical data readout announcement that is not a full financial report is often classified under general corporate news or regulatory updates. However, given the options, this is a significant corporate announcement detailing scientific progress and future regulatory plans. It is not a standard Earnings Release (ER) which focuses on financial metrics, nor is it a formal regulatory filing (RNS). It is a detailed scientific/clinical update. In the context of financial reporting databases, major clinical trial results announcements that precede formal filings are often categorized as Investor Presentations (IP) if they contain slides, or sometimes as Regulatory Filings (RNS) if they are the primary means of disclosure. Since this is a press release format detailing results that will be presented at a future congress, it strongly resembles an Investor Presentation (IP) in content focus (strategy, data, outlook), even if the format is a press release. However, if we strictly adhere to the definitions, it is a detailed announcement of scientific progress. Given the options, and recognizing this is a major corporate update on R&D progress, it aligns best with Investor Presentation (IP) content, or potentially Regulatory Filings (RNS) as a catch-all for significant non-standard announcements. Since it details the results of a Phase III trial and discusses future regulatory submissions, it is a key piece of information for investors, making 'IP' a strong candidate, although it is not explicitly a slide deck. Given the nature of the announcement (major clinical data readout), and lacking a specific 'Clinical Trial Result Announcement' code, 'IP' (Investor Presentation) is often used for such detailed scientific updates aimed at investors, or 'RNS' as a general regulatory announcement. I will lean towards 'IP' as the content is highly focused on the drug's potential and trial data, which is the core of an investor presentation, even if delivered via press release.
2023-06-30 French
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease
Regulatory Filings Classification · 1% confidence The document is a press release jointly issued by Ipsen and GENFIT announcing positive topline data from the Phase III ELATIVE trial for the drug elafibranor in treating Primary Biliary Cholangitis (PBC). It details efficacy endpoints, safety profiles, and future intentions to submit regulatory applications to the FDA and EMA. This content—announcing clinical trial results and subsequent regulatory plans—is characteristic of a major corporate update related to drug development and commercialization. It is not a full Annual Report (10-K), a formal Audit Report (AR), a transcript (CT), or a simple Earnings Release (ER) which usually focuses on revenue/profit. Since it is a detailed announcement of clinical trial success and the next steps toward market approval, it best fits the category for general corporate/investor information that isn't strictly financial reporting or management changes. Given the options, this is a significant corporate announcement that doesn't fit the highly specific categories like DIV, DIRS, or DEF 14A. It is most closely aligned with a general Investor Relations announcement or a Regulatory Filing announcement, but since it contains substantial narrative and data, it is more than just a 'Report Publication Announcement' (RPA). However, in the context of financial filings, major clinical trial results announcements often fall under general Regulatory Filings (RNS) or sometimes Investor Presentations (IP) if it were a slide deck. Since this is a press release detailing results and future regulatory steps, and it is not a formal regulatory form like 10-K or a specific financial report, RNS (Regulatory Filings - general regulatory announcements) is the most appropriate fallback, although it strongly resembles an Investor Presentation summary. Given the focus on trial results and regulatory intent, RNS is chosen as the best fit among the provided codes for a major, non-standardized corporate announcement.
2023-06-30 English
Ipsen annonce les résultats positifs du comité consultatif de la FDA sur le palovarotène expérimental pour la fibrodysplasie ossifiante progressive
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen, dated June 29, 2023, announcing positive results from an FDA advisory committee meeting regarding their experimental drug, palovarotene, for FOP. It details the voting outcomes (10-4 and 11-3) and mentions the upcoming PDUFA date (August 16, 2023). This content is characteristic of an initial announcement of key clinical/regulatory milestones, often released before the full quarterly or annual report, and focuses on specific, timely news rather than comprehensive financial statements or management structure changes. It is not a full Annual Report (10-K), an Interim Report (IR), a Call Transcript (CT), or a formal Audit Report (AR). It is a specific news release about drug development progress. While it contains financial context (revenue for 2022), its primary purpose is regulatory/clinical news dissemination. This fits best under the 'Earnings Release' (ER) category as it announces key performance/regulatory milestones, or potentially 'Regulatory Filings' (RNS) if it were a more generic update. Given the focus on positive results leading up to a regulatory decision, ER is the closest fit for a major corporate announcement of this nature, even if it's not strictly quarterly earnings.
2023-06-29 French
Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen dated June 29, 2023, announcing a positive outcome from an FDA Advisory Committee meeting regarding their investigational drug palovarotene for FOP. It details the voting results (10-4 for efficacy, 11-3 for risk/benefit) and mentions the upcoming FDA PDUFA action date (August 16, 2023). This content is a specific announcement of clinical/regulatory progress and results, not a comprehensive annual report (10-K), a quarterly report (IR), or a general earnings release (ER). It is a specific type of regulatory/clinical update. Since it is an announcement about a drug development milestone and regulatory review status, it fits best under the general 'Regulatory Filings' (RNS) category as a significant corporate announcement that doesn't map to the more specific financial or governance codes. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Audit Report (AR). Given the nature of the announcement (FDA advisory committee outcome), it is a material event disclosure.
2023-06-29 English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 25 - 2023
Director's Dealing Classification · 1% confidence The document text consists of detailed tables showing transactions involving the issuer 'IPSEN' on specific dates (e.g., 19/06/2023, 20/06/2023). The tables list 'Volume total journalier (en nombre d'actions)' and 'Prix pondéré moyen journalier d'acquisition des actions', and later detail specific transactions including 'Quantité achetée' and 'Prix Unitaire'. This structure is characteristic of mandatory regulatory filings reporting insider transactions or significant share dealings by directors/executives. Comparing this content to the definitions, it directly matches the description for Director's Dealing (DIRS), which covers reports of personal share transactions by directors and executives (insider trades). Although the text is in French, the content clearly indicates insider trading reports.
2023-06-27 French
IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023
Director's Dealing Classification · 1% confidence The document text consists primarily of tables detailing transactions involving the issuer 'IPSEN'. Key columns include 'Name of issuer', 'Day of transaction', 'Aggregated daily volume (in number of shares)', and 'Daily weighted average price'. The presence of transaction dates (e.g., 19/06/2023, 20/06/2023) and specific details about share volume and price strongly indicates a report detailing personal share transactions by directors or executives, or transactions conducted by an investment service provider on behalf of an insider/the company itself. This aligns perfectly with the definition of Director's Dealing (DIRS) or Transaction in Own Shares (POS). Since the data shows transactions executed by 'Exane SA' (an investment service provider) involving IPSEN shares, and the structure resembles regulatory disclosures for insider/significant transactions, 'DIRS' (Director's Dealing) is the most appropriate classification, as these reports often cover transactions by persons discharging managerial responsibilities (PDMRs) or related parties, which is a common context for such detailed transaction logs. If the transactions were explicitly stated as the company buying back its own stock, POS would be used, but the format suggests disclosure of transactions by an entity acting on behalf of insiders or related parties, fitting DIRS better in a general context of insider transaction reporting.
2023-06-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.